Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes

被引:127
|
作者
Liddle, C [1 ]
Goodwin, BJ
George, J
Tapner, M
Farrell, GC
机构
[1] Univ Sydney, Dept Clin Pharmacol, Westmead Hosp, Storr Liver Unit, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Hosp, Dept Med, Westmead, NSW 2145, Australia
来源
关键词
D O I
10.1210/jc.83.7.2411
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CYP3A4, the predominant cytochrome P450 expressed in human liver, is responsible for the metabolism of endogenous steroids and many drugs. On the basis of pharmacokinetic studies in patients with hormonal derangements and the effects of replacement therapy, it has been suggested that iodothyronines decrease CYP3A4-mediated drug metabolism, whereas glucocorticoids and GH enhance CYP3A4 activity. The aim of the present study, using well differentiated human hepatocytes in primary culture, was to examine directly whether hormonal factors regulate CYP3A4 gene expression. Addition of T-3 to primary hepatocytes resulted in a marked reduction of CYP3A4-catalyzed testosterone GP-hydroxylase activity and corresponding levels of CYP3A4 protein and messenger ribonucleic acid compared to those in untreated cells. Conversely, both dexamethasone and GH treatment substantially increased CYP3A4 gene expression. None of the hormones studied consistently altered the expression of other human cytochrome P450 genes. We conclude that iodothyronines, glucocorticoids, and GH act directly on human hepatocytes to regulate the expression of CYP3A4, and these effects appear to be exerted at a pretranslational level. Altered regulation of hepatic CYP3A4 is, therefore, likely to account for previous observations concerning the effects of endocrine diseases and hormonal treatments on human cytochrome P450-mediated drug and steroid metabolism.
引用
收藏
页码:2411 / 2416
页数:6
相关论文
共 50 条
  • [1] Dexamethasone induction of cytochrome P450 3A4 activity in human hepatocytes and healthy volunteers.
    McCune, J
    Hawke, R
    LeCluyse, E
    Gillenwater, H
    Ritchie, J
    Lindley, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 195 - 195
  • [2] Structures of cytochrome P450 3A4
    Scott, EE
    Halpert, JR
    TRENDS IN BIOCHEMICAL SCIENCES, 2005, 30 (01) : 5 - 7
  • [3] Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes
    Roymans, D
    Van Looveren, C
    Leone, A
    Parker, JB
    McMillian, M
    Johnson, MD
    Koganti, A
    Gilissen, R
    Silber, P
    Mannens, G
    Meuldermans, W
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (03) : 427 - 437
  • [4] The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes
    Lindley, C
    Hamilton, G
    McCune, JS
    Faucette, S
    Shord, SS
    Hawke, RL
    Wang, HB
    Gilbert, D
    Jolley, S
    Yan, BF
    LeCluyse, EL
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (07) : 814 - 822
  • [5] Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes
    Yang, LQ
    Yu, WF
    Cao, YF
    Gong, B
    Chang, Q
    Yang, GS
    WORLD JOURNAL OF GASTROENTEROLOGY, 2003, 9 (09) : 1959 - 1962
  • [6] Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes
    Li-Qun Yang Wei-Feng Yu Yun-Fei Cao Department of Anesthesiology
    World Journal of Gastroenterology, 2003, 9 (09) : 1959 - 1962
  • [7] Molecular modeling of cytochrome P450 3A4
    Szklarz, GD
    Halpert, JR
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (03) : 265 - 272
  • [8] Sertraline and cytochrome P450 3A4 in dysthymia
    Dunn, E
    Helpard, B
    Steiner, M
    BIOLOGICAL PSYCHIATRY, 1997, 41 : 116 - 116
  • [9] Molecular modeling of cytochrome P450 3A4
    Grazyna D. Szklarz
    James R. Halpert
    Journal of Computer-Aided Molecular Design, 1997, 11 : 265 - 272
  • [10] Molecular simulations of cytochrome P450 3A4
    Czapla, Luke
    Amaro, Rommie E.
    Kontoyianni, Maria
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243